1
|
Takada M, Kitagawa K, Zhang Y, Bulitta JB, Moirano S, Jones A, Borgen J, Onsager A, Thaiwong T, Vail DM. Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial. Vet Comp Oncol 2024. [PMID: 38889903 DOI: 10.1111/vco.12989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 05/20/2024] [Accepted: 05/22/2024] [Indexed: 06/20/2024]
Abstract
MAPK has been reported as a key oncogenic pathway for canine histiocytic sarcoma, which can be pharmacologically targeted with trametinib, a small inhibitor of MEK1/2. Preliminary data showed promising antitumor activity in in vitro and in vivo models and represented a proof of concept to translate the findings from bench to bedside. In this phase I, dose escalating study using a 3 + 3 cohort design, trametinib was evaluated in 18 dogs with cancer. Adverse events were graded according to VCOG-CTCAE v2. Blood samples and tumour biopsies were collected for pharmacokinetic and pharmacodynamic assessment. Trametinib was well tolerated with a maximum tolerated dose of 0.5 mg/m2/day, PO. Dose-limiting toxicities included systemic hypertension, proteinuria, lethargy and elevated ALP, and were all Grade 3. The drug exposures increased more than linearly with dose since the elimination of trametinib was saturable. At a dose of 500 μg Q24h (0.5 mg/m2/day in a 30 kg dog), approximately 70% of dogs had an average steady-state concentration of 10 ng/mL, achieved after approximately 2 weeks. This threshold was associated with clinical efficacy in humans. Target engagement was not observed in biospecimens collected on Days 0 and 7. In conclusion, trametinib was considered safe in dogs with cancer, and the dose of 0.5 mg/m2/day was the recommended dose for phase II studies.
Collapse
Affiliation(s)
- Marilia Takada
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
| | - Keita Kitagawa
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
| | - Yongzhen Zhang
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA
| | - Jürgen B Bulitta
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA
| | - Steven Moirano
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Abigail Jones
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Jennifer Borgen
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Ashley Onsager
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Tuddow Thaiwong
- Veterinary Diagnostic Laboratory, Michigan State University, Lansing, Michigan, USA
| | - David M Vail
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
2
|
Rinaldi V, Finotello R, Boari A, Cabibbo E, Crisi PE. Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma. Vet Sci 2023; 10:664. [PMID: 38133215 PMCID: PMC10747721 DOI: 10.3390/vetsci10120664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 11/17/2023] [Accepted: 11/20/2023] [Indexed: 12/23/2023] Open
Abstract
Vinorelbine (VRL), a semi-synthetic vinca alkaloid commonly used in humans with advanced lung cancer, reaches high concentrations in the lung tissue, has proven antineoplastic activity and a low toxicity profile in dogs. Treatment-naïve, client-owned dogs with a cyto/histological diagnosis of advanced pulmonary carcinoma, selected from a laboratory database and previously subjected to imaging, were enrolled in the study. Vinorelbine (15 mg/m2) was administered weekly for 4 weeks and then fortnightly until progressive disease was documented. Staging work-up was repeated by means of diagnostic imaging after the fourth VRL (i.e., 28 days) and monthly thereafter; response to treatment was evaluated according to the RECIST. Toxicity was graded following the VCOGC group. Ten dogs met the inclusion criteria. Partial response was documented in eight dogs. Median time to progression was 88 days (range: 7-112) and median survival time for all dogs was 100 days (range 7-635). The most common side effect was neutropenia. The main limitations of the study were the absence of histological diagnosis in eight cases and the limited number of treated dogs. VRL is well tolerated with an adequate toxicity profile and may be useful in the management of advanced lung tumours if used as a first-line treatment strategy.
Collapse
Affiliation(s)
- Valentina Rinaldi
- Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy; (A.B.)
| | - Riccardo Finotello
- Polo Oncologico Veterinario, AniCura Italy Holding S.r.l., 40100 Bologna, Italy
| | - Andrea Boari
- Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy; (A.B.)
| | | | - Paolo Emidio Crisi
- Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy; (A.B.)
| |
Collapse
|
3
|
Hernández-Suárez B, Gillespie DA, Dejnaka E, Kupczyk P, Obmińska-Mrukowicz B, Pawlak A. Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs. Front Vet Sci 2023; 10:1227683. [PMID: 37655260 PMCID: PMC10467447 DOI: 10.3389/fvets.2023.1227683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Accepted: 07/31/2023] [Indexed: 09/02/2023] Open
Abstract
Background Dogs present a significant opportunity for studies in comparative oncology. However, the study of cancer biology phenomena in canine cells is currently limited by restricted availability of validated antibody reagents and techniques. Here, we provide an initial characterization of the expression and activity of key components of the DNA Damage Response (DDR) in a panel of hematopoietic canine cancer cell lines, with the use of commercially available antibody reagents. Materials and methods The techniques used for this validation analysis were western blot, qPCR, and DNA combing assay. Results Substantial variations in both the basal expression (ATR, Claspin, Chk1, and Rad51) and agonist-induced activation (p-Chk1) of DDR components were observed in canine cancer cell lines. The expression was stronger in the CLBL-1 (B-cell lymphoma) and CLB70 (B-cell chronic lymphocytic leukemia) cell lines than in the GL-1 (B-cell leukemia) cell line, but the biological significance of these differences requires further investigation. We also validated methodologies for quantifying DNA replication dynamics in hematopoietic canine cancer cell lines, and found that the GL-1 cell line presented a higher replication fork speed than the CLBL-1 cell line, but that both showed a tendency to replication fork asymmetry. Conclusion These findings will inform future studies on cancer biology, which will facilitate progress in developing novel anticancer therapies for canine patients. They can also provide new knowledge in human oncology.
Collapse
Affiliation(s)
- Beatriz Hernández-Suárez
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland
| | - David A. Gillespie
- Facultad de Medicina, Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Tenerife, Spain
| | - Ewa Dejnaka
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland
| | - Piotr Kupczyk
- Division of General and Experimental Pathology, Department of Clinical and Experimental Pathology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland
| | - Bożena Obmińska-Mrukowicz
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland
| | - Aleksandra Pawlak
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland
| |
Collapse
|
4
|
Regan D, Garcia K, Thamm D. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development. ILAR J 2019; 59:99-110. [PMID: 30668709 DOI: 10.1093/ilar/ily019] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 11/26/2018] [Indexed: 01/21/2023] Open
Abstract
The role of comparative oncology in translational research is receiving increasing attention from drug developers and the greater biomedical research community. Pet dogs with spontaneous cancer are important and underutilized translational models, owing to dogs' large size and relative outbreeding, combined with their high incidence of certain tumor histotypes with significant biological, genetic, and histological similarities to their human tumor counterparts. Dogs with spontaneous tumors naturally develop therapy resistance and spontaneous metastasis, all in the context of an intact immune system. These fundamental features of cancer biology are often lacking in induced or genetically engineered preclinical tumor models and likely contribute to their poor predictive value and the associated overall high failure rate in oncology drug development. Thus, the conduct of clinical trials in pet dogs with naturally occurring cancer represents a viable surrogate and valuable intermediary step that should be increasingly incorporated into the cancer drug discovery and development pipeline. The development of molecular-targeted therapies has resulted in an expanded role of the pathologist in human oncology trials, and similarly the expertise of veterinary pathologists will be increasingly valuable to all phases of comparative oncology trial design and conduct. In this review, we provide a framework of clinical, ethical, and pathology-focused considerations for the increasing integration of translational research investigations in dogs with spontaneous cancer as a means to accelerate clinical cancer discovery and drug development.
Collapse
Affiliation(s)
- Daniel Regan
- Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado
| | - Kelly Garcia
- Biologic Resources Laboratory, University of Illinois, Chicago, Illinois
| | - Douglas Thamm
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado
| |
Collapse
|
5
|
Tan YJ, Crowley RJ, Ioannidis JPA. An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs. Sci Rep 2019; 9:11877. [PMID: 31417164 PMCID: PMC6695388 DOI: 10.1038/s41598-019-48425-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Accepted: 07/26/2019] [Indexed: 11/23/2022] Open
Abstract
Comparative clinical trials of domestic dogs with spontaneously-occurring cancers are increasingly common. Canine cancers are likely more representative of human cancers than induced murine tumors. These trials could bridge murine models and human trials and better prioritize drug candidates. Such investigations also benefit veterinary patients. We aimed to evaluate the design and reporting practices of clinical trials containing ≥2 arms and involving tumor-bearing dogs. 163 trials containing 8552 animals were systematically retrieved from PubMed (searched 1/18/18). Data extracted included sample sizes, response criteria, study design, and outcome reporting. Low sample sizes were prevalent (median n = 33). The median detectable hazard ratio was 0.3 for overall survival and 0.06 for disease progression. Progressive disease thresholds for studies that did not adopt VCOG-RECIST guidelines varied in stringency. Additionally, there was significant underreporting across all Cochrane risk of bias categories. The proportion of studies with unclear reporting ranged from 44% (randomization) to 94% (selective reporting). 72% of studies also failed to define a primary outcome. The present study confirms previous findings that clinical trials in dogs need to be improved, particularly regarding low statistical power and underreporting of design and outcomes.
Collapse
Affiliation(s)
- Yuan Jin Tan
- Department of Health Research and Policy, Division of Epidemiology, Stanford School of Medicine, Stanford, CA, USA.,Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA
| | - Ryan J Crowley
- Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA, USA.,Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA
| | - John P A Ioannidis
- Department of Health Research and Policy, Division of Epidemiology, Stanford School of Medicine, Stanford, CA, USA. .,Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA, USA. .,Stanford Prevention Research Center, Department of Medicine, and Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA. .,Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA.
| |
Collapse
|
6
|
Aresu L, Buracco P, De Maria R, Iussich S, Martano M, Morello E, Bettini G, Comazzi S, Riondato F, Marconato L. The Italian-Canine Cancer Biobank: Our 10-year challenge. Hematol Oncol 2019; 37:314-315. [PMID: 30835862 DOI: 10.1002/hon.2602] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2019] [Revised: 02/20/2019] [Accepted: 03/01/2019] [Indexed: 01/20/2023]
Affiliation(s)
- Luca Aresu
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Paolo Buracco
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Raffaella De Maria
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Selina Iussich
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Marina Martano
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Emanuela Morello
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Giuliano Bettini
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy.,Dipartimento di Scienze Mediche Veterinarie, Università degli Studi di Bologna, Bologna, Italy
| | - Stefano Comazzi
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy.,Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, Milano, Italy
| | - Fulvio Riondato
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy
| | - Laura Marconato
- Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Torino, Italy.,Centro Oncologico Veterinario, Sasso Marconi, Italy
| |
Collapse
|
7
|
Slagle CJ, Thamm DH, Randall EK, Borden MA. Click Conjugation of Cloaked Peptide Ligands to Microbubbles. Bioconjug Chem 2018; 29:1534-1543. [DOI: 10.1021/acs.bioconjchem.8b00084] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Connor J. Slagle
- Department of Mechanical Engineering, University of Colorado, Boulder, Colorado 80309, United States
| | | | | | - Mark A. Borden
- Department of Mechanical Engineering, University of Colorado, Boulder, Colorado 80309, United States
| |
Collapse
|
8
|
Foskett A, Manley C, Naramore R, Gordon IK, Stewart BM, Khanna C. Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer. VETERINARY MEDICINE-RESEARCH AND REPORTS 2017; 8:97-102. [PMID: 30050861 PMCID: PMC6042486 DOI: 10.2147/vmrr.s149678] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The US Food and Drug Administration approved sorafenib in human patients with liver, thyroid, or renal carcinoma. The aim of this study was to help guide future pharmacokinetic (PK) studies of sorafenib in dogs with a cancer diagnosis. Client-owned dogs were eligible if they had a cytologic or histologic diagnosis of cancer. Patients were enrolled at escalating doses of sorafenib. Patients were evaluable for the study if they received at least one dose of sorafenib and presented 1 week later for a follow-up examination, blood work, and assessment of drug tolerability. The goal of this study was not to define a maximum tolerated dose as may be reasonable in conventional cytotoxic chemotherapy drugs, but rather to describe the tolerability of this drug in dogs with a cancer diagnosis, as a prequel to future sorafenib PK studies. No patients in the study had any evidence of adverse events that were attributable to sorafenib. Doses of 3 mg/kg were well tolerated and associated with a suggestion of clinical activity, supportive of future PK, and pharmacodynamic analysis. Such future studies are recommended at this dose to define the associated exposure achieved and determine a reasonable schedule for sorafenib administration.
Collapse
|
9
|
Pellin MA, Wouda RM, Robinson K, Tsimbas K, Kurzman ID, Biller BJ, Vail DM. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study. Vet Comp Oncol 2016; 15:919-931. [DOI: 10.1111/vco.12232] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 02/22/2016] [Accepted: 03/14/2016] [Indexed: 01/10/2023]
Affiliation(s)
- M. A. Pellin
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
| | - R. M. Wouda
- Kansas State University, College of Veterinary Medicine; Manhattan KS USA
| | - K. Robinson
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
| | - K. Tsimbas
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
| | - I. D. Kurzman
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
| | - B. J. Biller
- Flint Animal Cancer Center; Colorado State University; Fort Collins CO USA
| | - D. M. Vail
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
- Carbone Cancer Center; University of Wisconsin-Madison; Madison WI USA
| |
Collapse
|
10
|
Kaeberlein M, Creevy KE, Promislow DEL. The dog aging project: translational geroscience in companion animals. Mamm Genome 2016; 27:279-88. [PMID: 27143112 DOI: 10.1007/s00335-016-9638-7] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 04/15/2016] [Indexed: 12/16/2022]
Abstract
Studies of the basic biology of aging have identified several genetic and pharmacological interventions that appear to modulate the rate of aging in laboratory model organisms, but a barrier to further progress has been the challenge of moving beyond these laboratory discoveries to impact health and quality of life for people. The domestic dog, Canis familiaris, offers a unique opportunity for surmounting this barrier in the near future. In particular, companion dogs share our environment and play an important role in improving the quality of life for millions of people. Here, we present a rationale for increasing the role of companion dogs as an animal model for both basic and clinical geroscience and describe complementary approaches and ongoing projects aimed at achieving this goal.
Collapse
Affiliation(s)
- Matt Kaeberlein
- Department of Pathology, University of Washington, Seattle, WA, USA.
| | - Kate E Creevy
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | | |
Collapse
|
11
|
Frazier JP, Beirne E, Ditzler SH, Tretyak I, Casalini JR, Thirstrup DJ, Knoblaugh S, Ward JG, Tripp CD, Klinghoffer RA. Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model. Vet Comp Oncol 2016; 15:754-763. [PMID: 26991424 DOI: 10.1111/vco.12215] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Revised: 12/02/2015] [Accepted: 12/23/2015] [Indexed: 11/28/2022]
Abstract
Spontaneously occurring soft tissue sarcoma (STS) is relatively common in canine cancer patients. Because of the similarities to human disease, canine STSs are a valuable and readily available resource for the study of new therapeutics. In this study, a canine patient-derived xenograft (PDX) model, CDX-STS2, was established. The CDX-STS2 model was engrafted and expanded for systemic administration studies with chemotherapeutic agents commonly used to treat STS, including doxorubicin, docetaxel and gemcitabine. Immunohistochemistry for drug-specific biomarkers and tumour growth measurement revealed tumour sensitivity to doxorubicin and docetaxel, whereas gemcitabine had no effect on tumour growth. Although many human PDX tumour models have been established, relatively few canine PDX models have been reported to date. CDX-STS2 represents a new STS PDX research model of canine origin that will be useful in bridging preclinical research with clinical studies of STS in pet dogs.
Collapse
Affiliation(s)
| | - E Beirne
- Presage Biosciences, Seattle, WA, USA
| | | | - I Tretyak
- Presage Biosciences, Seattle, WA, USA
| | | | | | - S Knoblaugh
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA
| | - J G Ward
- Specialty VetPath, Shoreline, WA, USA
| | - C D Tripp
- Veterinary Cancer Specialty Care, Lynnwood, WA, USA
| | | |
Collapse
|
12
|
Page R, Baneux P, Vail D, Duda L, Olson P, Anestidou L, Dybdal N, Golab G, Shelton W, Salgaller M, Hardy C. Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations. J Vet Intern Med 2016; 30:527-35. [PMID: 26950524 PMCID: PMC4913608 DOI: 10.1111/jvim.13916] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 12/07/2015] [Accepted: 02/02/2016] [Indexed: 12/24/2022] Open
Abstract
Development of effective and safe treatments for companion animals with cancer requires the collaboration of numerous animal health professionals and the full engagement of animal owners. Establishing ‘Best Practice Recommendations’ for clinical trials in veterinary oncology represents an important step toward meeting the goal of rigorous clinical trial design and conduct that is required to establish valid evidence. Likewise, optimizing patient welfare and owner education and advocacy is crucial to meet the unique ethical obligations to both owners and animals enrolled in these clinical trials and to ensure trust in the team conducting the research. To date, ‘Best Practice Recommendations’ for clinical trial conduct have not been reported for veterinary oncology. This document summarizes the consensus of a workshop held in November, 2014 to identify relevant ethical principles and to ensure responsible conduct of clinical research in companion animals with cancer. It is intended as a working document that will be updated as advances in science and ethical considerations require. To the extent possible, existing guidelines for the conduct and oversight of clinical trials in humans have been adapted for veterinary trials to avoid duplicative effort and to facilitate integration of clinical trials such that translational research with benefits for both companion animals and humans are encouraged.
Collapse
Affiliation(s)
- R Page
- Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
| | | | - D Vail
- School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - L Duda
- School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - P Olson
- Olson Consulting, Animal Health and Welfare, Fort Collins, CO
| | - L Anestidou
- Institute for Laboratory Animal Research, National Academy of Sciences, Washington, DC
| | - N Dybdal
- Genentech, Inc., South San Francisco, CA
| | - G Golab
- American Veterinary Medical Association, Schaumburg, IL
| | - W Shelton
- Virtual Beast Consulting, San Mateo, CA
| | | | - C Hardy
- Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
| |
Collapse
|
13
|
Rasmussen RM, Kurzman ID, Biller BJ, Guth A, Vail DM. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs. Vet Comp Oncol 2015; 15:421-430. [DOI: 10.1111/vco.12179] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Revised: 08/24/2015] [Accepted: 08/24/2015] [Indexed: 12/30/2022]
Affiliation(s)
- R. M. Rasmussen
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
| | - I. D. Kurzman
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
| | - B. J. Biller
- Flint Animal Cancer Center; Colorado State University; Fort Collins CO USA
| | - A. Guth
- Flint Animal Cancer Center; Colorado State University; Fort Collins CO USA
| | - D. M. Vail
- Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA
- The Carbone Cancer Center; University of Wisconsin-Madison; Madison WI USA
| |
Collapse
|
14
|
Blomme EAG. Veterinary oncology: Translating research advances into innovative therapeutic and diagnostic options. Vet J 2015; 205:117-9. [PMID: 26095035 DOI: 10.1016/j.tvjl.2015.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Accepted: 06/04/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Eric A G Blomme
- Scientific Editor, The Veterinary Journal. AbbVie Inc., North Chicago, IL, USA..
| |
Collapse
|
15
|
Small molecule kinase inhibitors in veterinary oncology. Vet J 2015; 205:122-3. [PMID: 25744806 DOI: 10.1016/j.tvjl.2015.01.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Accepted: 01/28/2015] [Indexed: 12/25/2022]
|